A. Vlot

Factor VIII inhibitor in a patient with mild haemophilia A and an Asn618→Ser mutation responsive to immune tolerance induction and cyclophosphamide

J. Voorberg, H. M. van den Berg, E. Mauser-Bunschoten, 2002, British journal of haematology.

Treatment of a severely bleeding patient without preexisting coagulopathy with activated recombinant factor VII.

C. Gaillard, A. Mackaay, E. Ton, 2000, The American journal of medicine.

Iron refractory iron deficiency anemia: a heterogeneous disease that is not always iron refractory

D. Swinkels, M. Nijziel, R. Smeets, 2016, American journal of hematology.

Factor VIII and von Willebrand Factor

J. Sixma, B. Bouma, A. Vlot, 1998, Thrombosis and Haemostasis.

The Half-life of Infused Factor VIII Is Shorter in Hemophiliac Patients with Blood Group 0 than in those with Blood Group A

J. Sixma, H. M. van den Berg, E. Mauser-Bunschoten, 2000, Thrombosis and Haemostasis.

Antibodies that stop the adrenals in their tracks

A. V. D. Molen, R. Fijnheer, M. J. Muis, 2001, The Lancet.

Atrial fibrillation in cancer: thromboembolism and bleeding in daily practice.

H. Gelderblom, H. Versteeg, F. Klok, 2023, Research and practice in thrombosis and haemostasis.

Thromboembolic and bleeding complications during interruptions and after discontinuation of anticoagulant treatment in patients with atrial fibrillation and active cancer: A daily practice evaluation.

H. Gelderblom, H. Versteeg, S. Cannegieter, 2023, Thrombosis research.